424 related articles for article (PubMed ID: 34244276)
1. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.
Hussein H; Zaccardi F; Dhalwani NN; Davies MJ; Khunti K; Gray LJ
BMJ Open; 2018 Nov; 8(11):e023206. PubMed ID: 30413509
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129
[TBL] [Abstract][Full Text] [Related]
7. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
8. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
[TBL] [Abstract][Full Text] [Related]
10. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
11. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
Trombara F; Cosentino N; Bonomi A; Ludergnani M; Poggio P; Gionti L; Baviera M; Colacioppo P; Roncaglioni MC; Leoni O; Bortolan F; Agostoni P; Genovese S; Marenzi G
Cardiovasc Diabetol; 2023 Feb; 22(1):26. PubMed ID: 36747186
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
[TBL] [Abstract][Full Text] [Related]
13. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
Sohn M; Dietrich JW; Nauck MA; Lim S
Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
17. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
[TBL] [Abstract][Full Text] [Related]
19. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
20. Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease.
Trueman C; Shin E; Donovan A; McAdam-Marx C; Coan C
J Manag Care Spec Pharm; 2023 Dec; 29(12):1275-1283. PubMed ID: 38058135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
